Botanix Pharmaceuticals Stock (OTC: BXPHF)

Latest news for Botanix Pharmaceuticals (OTC:BXPHF) Stock

Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AAMMF

ACNNF

ACRT

AGFAF

AGTEF

AGTK

ALTERNATE HEALTH CORP ORD by Alternate Health Corp.

AHGIF

APPB

APRAF

ASCBQ

ASCJF

ASRRF

AWSM

AXCG

BIEI

BITRF

BKFCF

BKPPF

BKQNY

BLILF

BLKCF

BLOZF

BSRC

BTCY

CABA

CADMF

CASXF

CELZ

CERS

CETX

CGOTF

CHXMF

CKPT

CLYYF

CNAB

CONN

CPAI

CRUUF

CWVWF

CXRXF

DAUGF

DELRF

DGRI

DIGAF

DLUEY

DMHI

DPWW

DYNR

DYNT

EESE

ELLXF

ELRA

ENDV

ENRT

ESEA

EVTI

FAMI

FEIM

FNCTF

FRIVF

FSSN

FTFT

GAILF

GALT

GARS

GLYE

GNLN

GTEC

GTEH

GVLMF

HCMC

HGEN

HRCXF

HRVOF

HSNGY

HYSNF

ICNAF

IDRA

IFLM

IFRTF

IMMG

IPSEY

IPUB

IWSY

IZEA

JFIN

JILL

JTBK

KGET

KPAY

KPLUY

LATF

LEGE

LFER

LMPRF

Stocks That Hit 52-Week Lows On Tuesday

BOTANIX PHARMACEUTICALS by Botanix Pharmaceuticals Ltd.

Botanix Pharmaceuticals Ltd

Keefe, Bruyette &amp; Woods analyst Timothy Switzer reiterates Live Oak Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOB#NYSE">LOB</a>) with a Market Perform and raises the price target from $40 to $47.

Price Target

Reiteration

Analyst Ratings

Keefe, Bruyette & Woods Reiterates Market Perform on Live Oak Bancshares, Raises Price Target to $47

Norwood Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWFL#NASDAQ">NWFL</a>) reported quarterly earnings of $0.52 per share. This is a 35.8 percent decrease over earnings of $0.81 per share from the same period last year.

Earnings

NWFL

Norwood Financial Q2 EPS $0.52 Down From $0.81 YoY

CASY

Casey's General Stores To Acquire Fikes Wholesale For $1.145B, Expanding Presence In Texas And Southern Markets; Net After-Tax Purchase Price Is $980M

Keefe, Bruyette &amp; Woods analyst Aidan Hall reiterates Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) with a Outperform and raises the price target from $49 to $56.

Keefe, Bruyette & Woods Reiterates Outperform on Lazard, Raises Price Target to $56

Wells Fargo analyst Elyse Greenspan maintains Globe Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) with a Overweight and raises the price target from $105 to $108.

Wells Fargo Maintains Overweight on Globe Life, Raises Price Target to $108

Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) and Tencent Holdings have quickly integrated Meta Platforms Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) latest artificial intelligence (AI) model Llama 3.1 into their cloud services.
Alibaba Cloud, the e-commerce giant&#8217;s online computing platform, was among the first to include the latest open-source Llama family of large language models (LLMs), SCMP <a target="_blank" href="https://www.scmp.com/tech/tech-trends/article/3271858/ai-race-alibaba-tencent-quickly-adopt-metas-new-llama-31-model-amid-excitement" rel="noreferrer noopener">reports</a>.
This technology underpins generative AI products like ChatGPT.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/07/39901098/apple-and-micron-leaders-visit-beijing-as-us-intensify-advanced-semiconductor-sanctions-report" rel="noreferrer noopener">Apple and Micron Leaders Visit Beijing As US Intensify Advanced Semiconductor Sanctions: Report</a>
Alibaba announced the integration on Tuesday, offering one month of free computing resources for training and inferencing tasks with Llama 3.1.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26032748/newplot-65.png" alt="" class="wp-image-458659" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26032748/newplot-65.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26032748/newplot-65-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Tencent soon followed with its announcement on the same day. Llama 3.1 is now available on Tencent&#8217;s cloud platform, featuring fine-tuning and inferencing tweaks to ensure the models&#8217; usability in intelligent conversation, text generation, and writing tasks.
Meta has positioned Llama 3.1 as a powerful alternative to leading closed-source models like OpenAI&#8217;s GPT-4.
U.S.-China geopolitical relations became strained following the Western counterpart&#8217;s <a target="_blank" href="https://www.benzinga.com/news/24/07/39938971/chip-stocks-nvidia-amd-and-others-see-more-selloff-on-wednesday-whats-going-on" rel="noreferrer noopener">advanced semiconductor sanctions</a> on the Asian counterpart, which included limiting AI chip access from the likes of Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and peers.
<a target="_blank" href="https://www.benzinga.com/government/24/04/38140039/us-embargo-on-nvidia-stings-hard-chinas-ai-development-lags-peers-alibabas-joe-tsai-reveals" rel="noreferrer noopener">A prior report quoted</a> Alibaba co-founder and chairman Joe Tsai acknowledging China&#8217;s lagging position in the&nbsp;AI development race, with Washington&#8217;s embargo taking a toll on their AI ambitions.&nbsp;
Alibaba stock has lost over 22% in the last 12 months as it strives to accomplish its AI ambitions amid a weak domestic economy crippled with intense rivalry.
Price Action: BABA shares closed lower by 0.25% at $75.21 premarket at the last check on Friday.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/07/39968313/nio-xpeng-li-auto-benefit-from-chinas-increased-vehicle-subsidies" rel="noreferrer noopener">Nio, XPeng, Li Auto Benefit From China&#8217;s Increased Vehicle Subsidies</a>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by Fooksou Lamimo via Wikimedia Commons

Tech

Media

BABA

NVDA

Alibaba And Tencent Lap Up Meta's AI Large Language Model

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains First Internet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBK#NASDAQ">INBK</a>) with a Market Perform and raises the price target from $36 to $42.

INBK

Keefe, Bruyette & Woods Maintains Market Perform on First Internet, Raises Price Target to $42

Wells Fargo analyst Elyse Greenspan maintains Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) with a Overweight and raises the price target from $318 to $321.

Wells Fargo Maintains Overweight on Willis Towers Watson, Raises Price Target to $321

RBC Capital analyst Michael Harvey reiterates Whitecap Res (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WCP#TSX">WCP</a>) with a Outperform and maintains C$14 price target.

TSX:WCP

RBC Capital Reiterates Outperform on Whitecap Res, Maintains C$14 Price Target

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Heritage Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>) with a Outperform and raises the price target from $10.5 to $11.5.

HTBK

Keefe, Bruyette & Woods Maintains Outperform on Heritage Commerce, Raises Price Target to $11.5

Creates a community-focused, regional financial services partner with $27+ billion in assets
Announces $200 million in capital commitments in support of the merger
WHEELING, W.Va., July 26, 2024 /PRNewswire/ -- WesBanco, Inc. ("WesBanco") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSBC#NASDAQ">WSBC</a>) and Premier Financial Corp. ("Premier") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFC#NASDAQ">PFC</a>) jointly announced today that they have executed a definitive Agreement and Plan of Merger ("Agreement") providing for the merger of Premier with and into WesBanco. Jeff Jackson, President and Chief Executive Officer of WesBanco, and Gary Small, President and Chief Executive Officer of Premier, made the joint announcement.
Under the terms of the Agreement, which has been unanimously approved by the board of directors of both companies, WesBanco will exchange shares of its common stock for all of the outstanding shares of Premier common stock, in an all-stock transaction. Premier shareholders will be entitled to receive 0.80 of a share of WesBanco common stock for each share of Premier common stock they own upon the effective time of the merger, for aggregate merger consideration valued at approximately $959 million, or $26.66 per share, based on WesBanco's closing stock price of $33.32 as of July 24, 2024. The transaction values Premier at a price to June 30, 2024 tangible book value per share of 142% and a price to mean analyst estimated 2024 earnings per share of 12.9 times. The merger is expected to qualify as a tax-free reorganization.

WSBC

WesBanco Announces Merger With Premier Financial, Premier Shareholders Will Be Entitled To Receive 0.80 Of A Share Of WesBanco Common Stock For Each Share Of Premier Common Stock They Own Upon The Effective Time Of The Merger, For Aggregate Merger Consideration Valued At ~$959M, Or $26.66 Per Share

Wells Fargo analyst Elyse Greenspan maintains Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) with a Overweight and raises the price target from $282 to $301.

Wells Fargo Maintains Overweight on Arthur J. Gallagher, Raises Price Target to $301

Oxford Lane Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXLC#NASDAQ">OXLC</a>) reported quarterly earnings of $0.41 per share which met the analyst consensus estimate. The company reported quarterly sales of $89.800 million which missed the analyst consensus estimate of $159.621 million by 43.74 percent. This is a 27.38 percent increase over sales of $70.500 million the same period last year.

Earnings Misses

OXLC

Oxford Lane Capital Q1 2025 Adj EPS $0.41, Inline, Sales $89.800M Miss $159.621M Estimate

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Horace Mann Educators (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMN#NYSE">HMN</a>) with a Outperform and lowers the price target from $42 to $40.

Keefe, Bruyette & Woods Maintains Outperform on Horace Mann Educators, Lowers Price Target to $40

Wells Fargo analyst Timur Braziler maintains Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) with a Equal-Weight and raises the price target from $22 to $26.

COLB

Wells Fargo Maintains Equal-Weight on Columbia Banking System, Raises Price Target to $26

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Heritage Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFWA#NASDAQ">HFWA</a>) with a Market Perform and raises the price target from $20 to $23.

HFWA

Keefe, Bruyette & Woods Maintains Market Perform on Heritage Financial, Raises Price Target to $23

Management

LAES

SEALSQ Appoints Katsu Miyahata As Sales Director And Representative Director For Japan; Miyahata To Lead Expansion Of IoT Security And Brand Enhancement Operations

Oxford Lane Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXLC#NASDAQ">OXLC</a>) reported quarterly earnings of $0.41 per share. This is a 4.65 percent decrease over earnings of $0.43 per share from the same period last year. The company reported $89.80 million in sales this quarter. This is a 27.38 percent increase over sales of $70.50 million the same period last year.

Oxford Lane Capital Q1 Adj $0.41 Down From $0.43 YoY, Sales $89.80M Up From $70.50M YoY

Wells Fargo analyst Jonathan Reeder maintains SJW Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NYSE">SJW</a>) with a Equal-Weight and raises the price target from $62 to $63.

Wells Fargo Maintains Equal-Weight on SJW Gr, Raises Price Target to $63

Friday,&nbsp;Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;posted second-quarter revenues of $12.20 billion, beating the consensus of $11.55 billion, an increase of 9% year-over-year, or 11% when adjusted for foreign exchange impacts, primarily driven by the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">Growth Portfolio and&nbsp;Eliquis</a>.
Growth Portfolio worldwide revenues increased to $5.6 billion compared to $4.7 billion a year ago, representing growth of 18% on a reported basis or 21% when adjusted for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b39980444/bristol-myers-squibb-reports-second-quarter-financial-results-for-2024" rel="noreferrer noopener">foreign exchange impacts</a>.
Growth Portfolio revenues were primarily driven by higher demand for&nbsp;Opdivo,&nbsp;Reblozyl, Camzyos, and&nbsp;Opdualag,&nbsp;partially offset by&nbsp;Abecma.
Related: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39454533/fda-approves-bristol-myers-squibbs-combination-therapy-for-colorectal-cancer-patients-with-certai" rel="noreferrer noopener">FDA Approves Bristol Myers Squibb&#8217;s Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation</a>.
Opdivo sales incresaed 11% to $2.39 billion. Abecma sales fell 28% to $95 million.
Revenues for the Legacy Portfolio in the second quarter were $6.6 billion compared to $6.5 billion a year ago, representing growth of 2% on a reported basis, or 3% when adjusted for foreign exchange impacts.
Legacy Portfolio revenues were driven by higher demand for&nbsp;Eliquis&nbsp;and&nbsp;Pomalyst, partially offset by a decline in&nbsp;Revlimid&nbsp;due to generic erosion. Eliquis sales were up 7% to $3.42 billion.
The company reported an adjusted EPS of $2.07, compared to an income of&nbsp;$1.75 a year&nbsp;ago, beating the consensus of $1.63.
&#8220;Our second quarter results reflect progress against our strategy to position BMS for long-term, sustainable growth. As we move into the second half of the year, we remain focused on prioritizing opportunities with the greatest growth potential and impact for patients, including the anticipated U.S. launch of KarXT. We&#8217;re also driving operational excellence throughout the company, becoming more agile and strengthening execution,&#8221; said Christopher Boerner, board chair and CEO.
Guidance:&nbsp;Bristol Myers Squibb revises 2024 adjusted EPS guidance to $0.60-$0.90 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38437857/bristol-myers-squibb-swings-to-quarterly-loss-after-string-of-multi-billion-acquisitions" rel="noreferrer noopener">versus prior guidance</a> of $0.40-$0.70 and consensus Of $0.51.
For 2024, the U.S. drug maker expects revenue growth to be at the upper end of the previously provided low single-digit range.
Price Action: BMY stock is up 5.17% at $47.61 during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/05/39118061/fda-expands-approval-for-bristol-myers-squibbs-breyanzi-making-car-t-cell-therapy-available-for-b" target="_blank" rel="noreferrer noopener">FDA Expands Approval For Bristol Myers Squibb&#8217;s Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies</a>.</li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

Bristol Myers Squibb Witnesses Strong Demand For 'Newer Drugs' As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast

Botanix Pharmaceuticals

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Botanix Pharmaceuticals

News

Latest news for Botanix Pharmaceuticals (OTC:BXPHF) Stock

Tuesday, December 10, 2019